Unmet need in rheumatology: Reports from the Targeted Therapies meeting 2018

Annals of the Rheumatic Diseases

Volumn 78, Issue 7, 2019, Pages 872-878

  Winthrop, Kevin L ^a   Weinblatt, Michael E ^b   Crow, Mary K ^c   Burmester, Gerd R ^d   Mease, Philip J ^e   So, Alexander K ^f   Bykerk, Vivian ^c   Van Vollenhoven, Ronald F ^g   Dougados, Maxime ^h   Kay, Jonathan ⁱ   Mariette, Xavier ^j   Sieper, Joachim ^d   Melchers, Fritz ^k,l   Cronstein, Bruce N ^m   Shevach, Ethan ⁿ   Breedfeld, Ferdinand C ^o   Kalden, Joachim ^p   Smolen, Josef S ^q   Furst, Daniel E ^e,r,s  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HOSPITAL FOR SPECIAL SURGERY   (United States)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY OF WASHINGTON   (United States)

^f UNIVERSITY OF LAUSANNE   (Switzerland)

^g Amsterdam Rheumatology and Immunology Center   (Netherlands)

^h Institut Cochin   (France)

ⁱ UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^j UNIVERSITÉ PARIS SACLAY   (France)

^k MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

^l DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

^m NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ NATIONAL INSTITUTES OF HEALTH   (United States)

^o LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^p UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^q MEDICAL UNIVERSITY OF VIENNA   (Austria)

^r UNIVERSITY OF CALIFORNIA   (United States)

^s UNIVERSITY OF FLORENCE   (Italy)

more..

Author keywords

ankylosing spondylitis; inflammatory myopathies; psoriatic arthritis; rheumatoid arthritis; sj gren's syndrome; spondyloarthritis; systemic lupus erythematosus; systemic sclerosis; vasculitis

Indexed keywords

ABATACEPT; BARICITINIB; BIOLOGICAL MARKER; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FILGOTINIB; GUSELKUMAB; INTERLEUKIN 17; INTERLEUKIN 23; IXEKIZUMAB; METHOTREXATE; RISANKIZUMAB; TILDRAKIZUMAB; TOFACITINIB; TUMOR NECROSIS FACTOR; UPADACITINIB; ANTIRHEUMATIC AGENT;

AFRICAN AMERICAN; ASIAN; CLINICAL FEATURE; COMORBIDITY; CONNECTIVE TISSUE DISEASE; CONSULTATION; DRUG DOSE ESCALATION; GENOME-WIDE ASSOCIATION STUDY; HEALTH CARE; HEALTH CARE NEED; HEALTH CARE QUALITY; HEALTH EDUCATION; HUMAN; IMMUNOLOGY; IMMUNOPATHOGENESIS; INCIDENCE; INTESTINE FLORA; MEDICAL RESEARCH; MOLECULAR BIOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; PATIENT REFERRAL; POPULATION BASED CASE CONTROL STUDY; POSITRON EMISSION TOMOGRAPHY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; RISK FACTOR; SCIENCE; SPONDYLARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; HEALTH SERVICE; ORGANIZATION; RHEUMATIC DISEASE;

ANTIRHEUMATIC AGENTS; CONGRESSES AS TOPIC; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; RHEUMATIC DISEASES; RHEUMATOLOGY;

EID: 85061076907     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2018-214280     Document Type: Review

References (60)

1. Furst DE, Keystone EC, So AK, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Ann Rheum Dis 2013;72 Suppl 2:ii2-34.
2. Singh JA, Saag KG, Bridges SL, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res 2016;68:1-25.
3. Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76:960-77.
4. Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 2016;75:499-510.
5. Winthrop KL, Strand V, van der Heijde DM, et al. The unmet need in rheumatology: reports from the targeted therapies meeting 2016. Clin Exp Rheumatol 2016;34(4 Suppl 98):69-76.
6. Winthrop KL, Strand V, van der Heijde D, et al. The unmet need in rheumatology: reports from the Targeted Therapies meeting 2017. Clin Immunol 2018;186.
7. Cook MJ, Diffin J, Scire CA, et al. Predictors and outcomes of sustained, intermittent or never achieving remission in patients with recent onset inflammatory polyarthritis: results from the Norfolk Arthritis Register. Rheumatology 2016;55:1601-9.
8. Ferriols-Lisart R, Ferriols-Lisart F. Dose modifications of anti-TNF drugs in rheumatoid arthritis patients under real-world settings: A systematic review. Rheumatol Int 2015;35:1193-210.
9. Dörner T, Strand V, Cornes P, et al. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis 2016;75:974-82.
10. Kay J, Winthrop K. Biosimilar switching: "to set a form upon desired change". Nature Rheumatology Reviews;13:391-2.
11. Kiely PD. Biologic efficacy optimization-a step towards personalized medicine. Rheumatology 2016;55:780-8.
12. Lee YC, Napadow V, Loggia ML. Editorial: Functional connectivity: dissecting the relationship between the brain and "pain centralization" in rheumatoid arthritis. Arthritis Rheumatol 2018;70:977-80.
13. Hopson S, Saverno K, Liu LZ, et al. Impact of out-of-pocket costs on prescription fills among new initiators of biologic therapies for rheumatoid arthritis. J Manag Care Spec Pharm 2016;22:122-30.
14. van der Meulen TA, Harmsen H, Bootsma H, et al. The microbiome-systemic diseases connection. Oral Dis 2016;22:719-34.
15. Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med 2017;376:957-70.
16. Orbai AM, de Wit M, Mease PJ, et al. Updating the psoriatic arthritis (PSA) core domain set: A report from the PSA workshop at OMERACT 2016. J Rheumatol 2017;44:1522-8.
17. Ogdie A, de Wit M, Callis Duffin K, et al. Defining outcome measures for psoriatic arthritis: A report from the GRAPPA-OMERACT Working Group. J Rheumatol 2017;44:697-700.
18. Kawalec P, Holko P, Moko P, et al. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: A systematic review and network meta-analysis. Rheumatol Int 2018;38:189-201.
19. Barnas JL, Ritchlin CT. Etiology and pathogenesis of psoriatic arthritis. Rheum Dis Clin North Am 2015;41:643-63.
20. Mease PJ, Armstrong AW. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs 2014;74:423-41.
21. Bilal J, Berlinberg A, Bhattacharjee S, et al. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis. J Dermatolog Treat 2018;29:569-78.
22. Haroon M, FitzGerald O. Psoriatic arthritis: complexities, comorbidities and implications for the clinic. Expert Rev Clin Immunol 2016;12:405-16.
23. Mease PJ GM, Weinblatt M, Peloso PM, et al. Safety and efficacy of ABT-122, a TNF and IL-17-Targeted Dual Variable Domain (DVD)-Ig™, in psoriatic arthritis patients with inadequate response to methotrexate: results from a phase 2 trial. Arthritis Rheumatol 2016;68(suppl 10).
24. Coates LC, FitzGerald O, Merola JF, et al. Group for research and assessment of psoriasis and psoriatic arthritis/outcome measures in rheumatology consensus-based recommendations and research agenda for use of composite measures and treatment targets in psoriatic arthritis. Arthritis Rheumatol 2018;70:345-55.
25. Jadon DR, Chandran V, Stober C, et al. Proceedings of The 2017 GRAPPA Collaborative Research network meeting. J Rheumatol Suppl 2018;94:54-61.
26. FitzGerald O, Haroon M, Giles JT, et al. Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype. Arthritis Res Ther 2015;17.
27. Ogdie A, Schwartzman S, Husni ME. Recognizing and managing comorbidities in psoriatic arthritis. Curr Opin Rheumatol 2015;27:118-26.
28. Mease PJ, Fibromyalgia MPJ. Fibromyalgia, a missed comorbidity in spondyloarthritis: prevalence and impact on assessment and treatment. Curr Opin Rheumatol 2017;29:304-10.
29. Genovese MC, Weinblatt ME, Aelion JA, et al. ABT-122, a bispecific DVDImmunoglobulin targeting TNF-and IL-17A, in RA with inadequate response to methotrexate: A randomized, double-blind study. Arthritis Rheumatol 2018;70:1710-20.
30. Cobo-Ibánez T, Villaverde V, Seoane-Mato D, et al. Multidisciplinary dermatology-rheumatology management for patients with moderate-to-severe psoriasis and psoriatic arthritis: A systematic review. Rheumatol Int 2016;36:221-9.
31. Velez NF, Wei-Passanese EX, Husni ME, et al. Management of psoriasis and psoriatic arthritis in a combined dermatology and rheumatology clinic. Archives of Dermatological Research 2012;304:7-13.
32. Okhovat JP, Ogdie A, Reddy SM, et al. Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN) survey: benefits and challenges of combined rheumatology-dermatology clinics. J Rheumatol 2017;44:693-4.
33. Van de Wiele T, Van Praet JT, Marzorati M, et al. How the microbiota shapes rheumatic diseases. Nature Reviews Rheumatology 2016;12:398-411.
34. Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet 2017;390:73-84.
35. Hall-Craggs MA, Bray TPJ, Bainbridge AP. Quantitative imaging of inflammatory disease: Are we missing a trick? Ann Rheum Dis 2018;77:1689-91.
36. Poddubnyy D, van Tubergen A, Landewé R, et al. Development of an ASASendorsed recommendation for the early referral of patients with a suspicion of axial spondyloarthritis. Ann Rheum Dis 2015;74:1483-7.
37. Poddubnyy D, Sieper J. What is the best treatment target in axial spondyloarthritis: tumour necrosis factor alpha, interleukin 17, or both? Rheumatology 2017.
38. Mease P, Sieper J, Van den Bosch F, et al. Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis. Arthritis Rheumatol 2015;67:914-23.
39. Li W, Sivakumar R, Titov AA, et al. Metabolic factors that contribute to Lupus pathogenesis. Critical Reviews in Immunology 2016;36:75-98.
40. Fernandez D, Perl A. Metabolic control of T cell activation and death in SLE. Autoimmunity Reviews 2009;8:184-9.
41. de Jesus AA, Canna SW, Liu Y, et al. Molecular mechanisms in genetically defined autoinflammatory diseases: disorders of amplified danger signaling. Annu. Rev. Immunol. 2015;33:823-74.
42. Elkon KB, Stone VV. Type I interferon and systemic lupus erythematosus. J Interferon Cytokine Res 2011;31:803-12.
43. Bialas AR, Presumey J, Das A, et al. Microglia-dependent synapse loss in type I interferon-mediated lupus. Nature 2017;30:539-43.
44. Berthier CC, Kretzler M, Davidson A. A systems approach to renal inflammation in SLE. Clinical Immunology 2017;185:109-18.
45. National Institutes of Health, 2018. Accelerating medicines partnership (AMP) secondary accelerating medicines partnership (AMP). Available: https://www. niams. nih. gov/ grants-funding/ funded-research/ accelerating-medicines
46. Wang Z, Long H, Chang C, et al. Crosstalk between metabolism and epigenetic modifications in autoimmune diseases: A comprehensive overview. Cellular and Molecular Life Sciences 2018;75:3353-69.
47. Langefeld CD, Ainsworth HC, Cunninghame Graham DS, et al. Transancestral mapping and genetic load in systemic lupus erythematosus. Nat Commun 2017;8.
48. Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009;61:1143-51.
49. Mahieu MA, Strand V, Simon LS, et al. A critical review of clinical trials in systemic lupus erythematosus. Lupus 2016;25:1122-40.
50. Fonseca R, Bernardes M, Terroso G, et al. Silent burdens in disease: fatigue and depression in SLE. Autoimmune Dis 2014;2014:1-9.
51. Cappelli LC, Gutierrez AK, Baer AN, et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 2017;76:43-50.
52. Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol 2016;2:234-40.
53. Nakaoka Y, Isobe M, Takei S, et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis 2018;77:348-54.
54. Khanna D, Denton CP, Lin CJF, et al. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). Ann Rheum Dis 2018;77:212-20.
55. Khanna D, Distler JHW, Sandner P, et al. Emerging strategies for treatment of systemic sclerosis. Journal of Scleroderma and Related Disorders 2016;1:186-93.
56. Sullivan KM, Goldmuntz EA, Keyes-Elstein L, et al. Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med 2018;378:35-47.
57. Nocturne G, Virone A, Ng W-F, et al. Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sjögren's syndrome. Arthritis Rheumatol 2016;68:977-85.
58. Fragkioudaki S, Mavragani CP, Moutsopoulos HM. Predicting the risk for lymphoma development in Sjogren syndrome: An easy tool for clinical use. Medicine 2016;95:e3766.
59. Yang H, Peng Q, Yin L, et al. Identification of multiple cancer-associated myositisspecific autoantibodies in idiopathic inflammatory myopathies: A large longitudinal cohort study. Arthritis Res Ther 2017;19.
60. Goulabchand R, Guilpain P, Cyteval C, et al. Anti-NXP2 antibody-associated extensive subcutaneous calcinosis in adult-onset myositis. Rheumatology 2017;56.